CD274 and diabetes mellitus: The latter indicated that PDAC-associated diabetes may be a distinct subtype of PDAC driven predominantly by immune mechanisms, suggesting that type 3c diabetes could render patients more sensitive to targeted immunotherapies (e.g., anti-PD-L1) compared to PDAC patients without diabetes.